What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr?

Vivienne C. M. Neeve, David C. Samuels, Laurence A. Bindoff, Bianca van den Bosch, Gert Van Goethem, Hubert Smeets, Anne Lombes, Claude Jardel, Michio Hirano, Salvatore DiMauro, Maaike C. de Vries, Jan Smeitink, Bart W. Smits, Ireneus F. M. de Coo, Carsten Saft, Thomas Klopstock, Bianca-Cortina Keiling, Birgit Czermin, Angela Abicht, Hanns LochmuellerGavin Hudson, Grainne G. Gorman, Doug M. Turnbull, Robert W. Taylor, Elke Holinski-Feder, Patrick F Chinnery, Rita Horvath*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Polymerase-gamma (POLG) is a major human disease gene and may account for up to 25% of all mitochondrial diseases in the UK and in Italy. To date, > 150 different pathogenic mutations have been described in POLG. Some mutations behave as both dominant and recessive alleles, but an autosomal recessive inheritance pattern is much more common. The most frequently detected pathogenic POLG mutation in the Caucasian population is c.1399G > A leading to a p.Ala467Thr missense mutation in the linker domain of the protein. Although many patients are homozygous for this mutation, clinical presentation is highly variable, ranging from childhood-onset Alpers-Huttenlocher syndrome to adult-onset sensory ataxic neuropathy dysarthria and ophthalmoparesis. The reasons for this are not clear, but familial clustering of phenotypes suggests that modifying factors may influence the clinical manifestation. In this study, we collected clinical, histological and biochemical data from 68 patients carrying the homozygous p.Ala467Thr mutation from eight diagnostic centres in Europe and the USA. We performed DNA analysis in 44 of these patients to search for a genetic modifier within POLG and flanking regions potentially involved in the regulation of gene expression, and extended our analysis to other genes affecting mitochondrial DNA maintenance (POLG2, PEO1 and ANT1). The clinical presentation included almost the entire phenotypic spectrum of all known POLG mutations. Interestingly, the clinical presentation was similar in siblings, implying a genetic basis for the phenotypic variability amongst homozygotes. However, the p.Ala467Thr allele was present on a shared haplotype in each affected individual, and there was no correlation between the clinical presentation and genetic variants in any of the analysed nuclear genes. Patients with mitochondrial DNA haplogroup U developed epilepsy significantly less frequently than patients with any other mitochondrial DNA haplotype. Epilepsy was reported significantly more frequently in females than in males, and also showed an association with one of the chromosomal markers defining the POLG haplotype. In conclusion, our clinical results show that the homozygous p.Ala467Thr POLG mutation does not cause discrete phenotypes, as previously suggested, but rather there is a continuum of clinical symptoms. Our results suggest that the mitochondrial DNA background plays an important role in modifying the disease phenotype but nuclear modifiers, epigenetic and environmental factors may also influence the severity of disease.
Original languageEnglish
Pages (from-to)3614-3626
Issue number12
Publication statusPublished - Dec 2012


  • mitochondrial diseases
  • neuromuscular disorders
  • genetics
  • phenotype
  • molecular biology


Dive into the research topics of 'What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr?'. Together they form a unique fingerprint.

Cite this